Next Phase Newsletter

A family office based in the US invests in pre-seed, seed and series A stage investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million. The firm may invest at later stages on a case-by-case basis. The firm invests across precision neuroscience, life sciences platforms, aerospace, digital deep tech, and climate tech. The firm prefers to invest in companies in conjunction with strong investment syndicate partners. The firm is open to opportunities worldwide. 
 
The firm’s life sciences funds early-stage companies across neurodegeneration, psychiatry and neurotech and also funds life science platform opportunities that raise the tide towards precision neuro. The firm invests across modalities. 
 
The firm invests in privately held companies and backs top scientists, who are pursuing breakthrough approaches rather than traditional. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm with main offices in China manages both RMB and USD funds. On average, the initial size of investment is in the $1-6M range, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm also manages innovation centers in China focusing on different special areas in Life Sciences and medical devices. With many years of operating experience of international medical technology incubators, the firm looks to tailor its services to help portfolio companies reaching key value-added milestones. The firm will consider opportunities based in China and around the globe. The firm actively supports global companies to fast land China market by leveraging the fund’s connections with leading hospitals and KOLs in China. 
 
The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, AI, and Biotechnology R&D Services. The firm is opportunistic in terms of sub-sector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. In terms of therapeutics, the firm will look at products in pre-clinical stages. Regarding medical devices and diagnostics, the firm will invest at any stage of development. 
 
The firm will invest in privately held companies only, and the firm can participate as either lead or co-investor. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital fund based in the US has invested the majority of its portfolio in the Life Sciences and HealthTech sectors. The firm plans to invest in two-or-three new portfolio companies and make one or two additional follow-on investments. The firm typically makes Pre-Seed, Seed and Series A investments ranging in size from $250K to $1M, and its largest total investment (including follow-ons) in any one company is $3.25M.  
 
The firm invests primarily in the Life Sciences and HealthTech sectors and in a wide range of sub-sectors within those sectors. The firm is sector and subsector agnostic and is open to evaluating different types of technologies. 
 
The firm invests in companies with growth-minded founders with proven track records, defensible market positions, and the ability to be positive cash-flow within 12-24 months. The firm is minority-owned and is committed to managing a diverse portfolio of companies with the potential to deliver above-average returns, including companies with minority, female and SEDI founders. The firm is an active investor that can provide valuable de-risking strategic and operational guidance and support through its venture studio, which helps portfolio companies reduce the risk of costly mistakes, get to market sooner and scale faster. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Founded in 2019, a Chinese venture capital firm is specialized in the growth-stage life science investments and IT area. Currently, the firm has 300M RMB assets under management. While generally being flexible on the allocation size, the firm typically makes investments ranging from 10-60 MM RMB (~1.4-8.5 MM USD). 
 
The firm has strong interest in investing novel pharmaceuticals, including orphan drugs. Also, the firm is open to digital health, especially the ones has big data application in life science area. So far, the firm has no interest in diagnostics nor medical devices products. 
 
The firm prefers companies with a China Angle, especially the ones open to register an entity in China. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A globally diversified healthcare venture capital firm has a mission is to deliver medical solutions and savings to over 100M people around the world. The firm seeks out visionary entrepreneurs who combine integrity, intelligence, and passion to address pressing healthcare challenges innovatively and ethically. The firm’s globally diversified portfolio comprises 60% allocation in the U.S. and the remaining 40% distributed across Singapore, India, and the EU. The firm’s engagement extends beyond financial investment. The firm provides robust post-investment support, focusing on strategy development, distribution, cross-border expansion, and manufacturing/OEM partnerships. They strive to establish an ecosystem that fosters collaboration among start-ups, government bodies, clinical, investment, and commercial partners. This approach ensures that portfolio companies receive comprehensive support, aiding in their growth and impactful contribution to the healthcare sector. 
 
Focused on early to growth-stage investments, the firm specializes in sectors including medical devices, digital health, healthcare services, and AI-empowered solutions. The firm has particular interests in critical areas such as oncology, ophthalmology, brain health, orthopedics, cardiology, and other chronic diseases management. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A deep tech and medical-focused venture capital firm based in Europe typically participates in early-stage, Seed to Series A financing rounds, with check sizes averaging between 1M and 1.5M EUR. Follow-on investment is possible. The firm seeks opportunities across Europe, excluding the UK, and is flexible in both leading and co-investing. The firm can be an active investor and may seek board or observer seats on a case-by-case basis. 
 
The firm is interested in medical devices, software, manufacturing and AI/machine learning related technologies. The firm also seeks novel approaches in tech bio, such as technologies that support drug discovery, drug development, expedite clinical trials, or gather real-world data. Other areas of interest include new genomic analysis. Traditional therapeutics are not of interest. The firm prefers to engage with companies early, and could interact with companies 1–2 years before the seed stage. 
 
The firm does not have specific requirements for a company’s founding team but prefers teams with diverse gender representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the US focuses on investing in early stage, typically pre-seed to Series A, across deeptech, life sciences, and the intersection between technology and healthcare in the U.S. market. The firm is backed by companies and family offices in the U.S., Europe, and Singapore, with partners that are all entrepreneurs in the life science space. The firm will usually co-invest with typical check sizes ranging from $100k-1M. The firm also partners with LPs for acquisition opportunities, and in those cases, they will do deals up to $100M but it is acquiring the company as opposed to investing. The firm plans to invest in 20 global companies per year in addition to incubating 1-2 companies a year. The firm is also willing to help companies go into emerging areas like Africa and Asia. 
 
The firm is opportunistic for life science and deeptech investments. Big focus areas for the firm include AI, health tech, neuroscience, life sciences tools, and therapeutics in the early-stage. The firm is also open to orphan diseases. In terms of therapeutics, the firm will invest in companies that are Pre-Clinical to Phase I. 
 
The firm does not have management team requirements and does not require taking a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.